The efficacy and tolerability of almotriptan 12.5 mg in acute migraine in patients who were poor responders to sumatriptan 50 mg: a randomized, placebo-controlled trial

被引：0
|
作者：
Diener, HC [1 ]
机构：
[1] Univ Essen Gesamthsch, Dept Neurol, Essen, Germany
来源：
CEPHALALGIA | 2004年 / 24卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：795 / 796
页数：2
相关论文
共 50 条
  • [21] Comparable efficacy of rofecoxib 12.5 mg and celecoxib 200 mg in the treatment of patients with osteoarthritis: A randomized, controlled trial
    Birbara, C
    Sheldon, E
    Farrell, J
    Rodgers, A
    Petruschke, R
    Robertson, D
    Chang, DJ
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 373 - 374
  • [22] A randomized, placebo-controlled, parallel-group trial of frovatriptan and sumatriptan for a single acute migraine attack
    Hutchison, J.
    Pfaffenrath, V.
    Geraud, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 144 - 144
  • [23] Treatment with sumatriptan 50 mg in the mildphase of migraine attacks in patients withinfrequent attacks: A randomised, double-blind,placebo-controlled study
    Tfelt-Hansen P.
    Bach F.W.
    Daugaard D.
    Tsiropoulos I.
    Riddersholm B.
    The Journal of Headache and Pain, 2006, 7 (6) : 389 - 394
  • [24] A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily Losartan 100 mg/hydrochlorothiazide 25 mg and Losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension
    Gradman, AH
    Brady, WE
    Gazdick, LP
    Lyle, P
    Zeldin, RK
    CLINICAL THERAPEUTICS, 2002, 24 (07) : 1049 - 1061
  • [25] Consistency of efficacy and tolerability of telcagepant 140 mg and 280 mg for the intermittent acute treatment of migraine: a multiple attack, double-blind, placebo-controlled study
    Ho, A. P.
    Dahlof, C.
    Silberstein, S.
    Saper, J.
    Ashina, M.
    Kost, J.
    Froman, S.
    Leibensberger, H.
    Lines, C.
    Ho, T. W.
    CEPHALALGIA, 2009, 29 (12) : 1354 - 1355
  • [26] The efficacy of 4mg sumatriptan subcutaneous injection for the treatment of moderate to severe migraine attacks: A double-blind, placebo-controlled trial
    Wendt, J
    Cady, R
    Singer, R
    Peters, K
    Webster, CJ
    Kori, S
    Byrd, S
    NEUROLOGY, 2006, 66 (05) : A255 - A255
  • [27] The Efficacy and Tolerability of Milnacipran 100 mg/day Monotherapy for the Management of Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial
    Arnold, Lesley M.
    Gendreau, R. Michael
    Spera, Allan
    Gendreau, Judy
    Wang, Yong
    NEUROLOGY, 2010, 74 (09) : A187 - A187
  • [28] Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial
    Boyer, Patrice
    Montgomery, Stuart
    Lepola, Ulla
    Germain, Jean-Michel
    Brisard, Claudine
    Ganguly, Rita
    Padmanabhan, Sudharshan K.
    Tourian, Karen A.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2008, 23 (05) : 243 - 253
  • [29] Efficacy, Safety, and Tolerability of Rimegepant 75 Mg, an Oral CGRP Receptor Antagonist, for the Acute Treatment of Migraine: Results from a Double-blind, Randomized, Placebo-controlled Trial, Study 302
    Lipton, R. B.
    Coric, V
    Stock, E. G.
    Stock, D.
    Morris, B. A.
    McCormack, T.
    Frost, M.
    Gentile, K.
    Conway, C. M.
    Croop, R.
    HEADACHE, 2018, 58 (08): : 1289 - 1289
  • [30] The efficacy and safety of sc Alniditan vs. sc Sumatriptan in the acute treatment of migraine:: a randomized, double-blind, placebo-controlled trial
    Diener, HC
    Tfelt-Hansen, P
    de Beukelaar, F
    Ferrari, MD
    Olesen, J
    Dahlöf, C
    Mathew, N
    CEPHALALGIA, 2001, 21 (06) : 672 - 679
12345